Tumor interaction with hemostasis: The rationale for the use of platelet inhibitors and anticoagulants in the treatment of cancer

Hamid Al‐Mondhiry

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations

Abstract

Clinical and experimental observations have firmly established the concept of a two‐way interaction between malignancy and the hemostatic system. On the one hand, certain tumors can activate platelets and the coagulation mechanism in vivo, on the other, a convincing case has been made for the involvement of platelets and fibrin in tumor growth and metastasis. A large number of clinical and experimental studies have been conducted in order to test the efficacy of platelet inhibitors and anticoagulants as adjuvants in the treatment of cancer. Antiplatelet drugs gave variable results, depending on the drug and the tumor system tested. Prostaglandin synthetic pathways by both the host and tumor seem to be an important determinant in the response to platelet function inhibitors. Of the various anticoagulants tested, the coumarin derivatives gave somewhat consistent antitumor effect in certain human and experimental cancer. The antitumor effect of oral anticoagulants does not appear to be a primary drug effect and seems related to their role as vitamin K antagonists. It should be emphasized that although the antitumor potential of antithrombotic agents is a subject of keen interest at the present, their use in treating human cancer is still controversial.

Original languageEnglish (US)
Pages (from-to)193-202
Number of pages10
JournalAmerican Journal of Hematology
Volume16
Issue number2
DOIs
StatePublished - Feb 1984

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Tumor interaction with hemostasis: The rationale for the use of platelet inhibitors and anticoagulants in the treatment of cancer'. Together they form a unique fingerprint.

Cite this